The therapy significantly reduced Dsg3 serum antibody levels and controlled disease progression in PV models without off-target cytotoxicity in keratinocytes or human skin xenograft mouse models, indicating a favorable safety profile. The gene discussed is DSG3; the disease is acquired polycythemia vera.